Staging of prostatic cancer before and after radical prostatectomy


Cite item

Full Text

Abstract

References

  1. Iversen P., Adolfsson J., Johansson J.-E. Localised prostate cancer: A Scandinavian view. Monogr. Urol. 1994; 15: 93-112.
  2. Fair W. R., Cookson M. S., Stoumbakis N. The indications, rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer. Urology 1997; 49 (suppl. ЗА): 46-55.
  3. Watson R. В., Soloway M. S. Neoadjuvant hormonal treatment before radical prostatectomy. Semin. Urol. Oncol. 1996; 14: 48-56.
  4. Грачева Л. С. Выявление и предоперационный прогноз клинически незначимого рака предстательной железы. Рус. мед. журн. 1997; 5 (4): 177-180.
  5. Epstein J. L., Pizov G., Walsh P. C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-3593.
  6. Ohori M., Wheeler T. M., Kattan M. W. et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. (Baltimore) 1995; 154: 1818-1824.
  7. Walsh P. C., Partin A. W., Epstein J. I. Cancer control and quality of life following anatomical radical prostatectomy: Results at 10 years. Ibid. 1994; 152: 1831-1836.
  8. Лоран О. Б., Пушкарь Д. Ю., Кан Я. Д. и др. Радикальная простатэктомия у больных раком предстательной железы без признаков экстракапсулярной инвазии. В кн.: Актуальные вопросы лечения онкоурологических заболеваний: Материалы 2-й Всероссийской конф. с участием стран СНГ. Обнинск; 1997. 156.
  9. Zincke H., Osterling J. E., Blute М. L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. (Baltimore) 1994; 152: 1850-1856.
  10. Partin A. W., Kattan M. W., Subong M. S. et al. Combination of prostate-specific antigen, clinical stage end Gleason score to predict pathological stage of localized prostate cancer: a multiinstitutional update. J. A. M. A. 1999; 277: 1445-1451.
  11. Partin A. W., Mangold L. A., Lamm D. M. et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-848.
  12. Blute M. L., Bergsrtalh E. J., Partin A. W. et al. Validation of Partin tables for predict pathological stage of clinically localized prostate cancer. J. Urol. (Baltimore) 2000; 165: 1591 - 1595.
  13. Tevari A., Narayan P. Novel stading tool for localized prostate cancer: A pilot study using genetic adaptive neural networks. Ibid. 1998; 160: 430-436.
  14. Reckwitz Т., Potter S. R., Partin A. W. Prediction of locoregional extension and metastatic diseases in prostate cancer: A review. Wld J. Urol. 2000; 18: 165-172.
  15. Матвеев Б. П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы. М.: ИЧП Фирма "РИЧА"; 1999.
  16. Friedman G. D., Hiatt R. A., Quesenberry С. P. et al. Case control study of screening for prostatic cancer by digital rectal examination. Lancet 1991; 337 (8756): 1526-1529.
  17. Красный С. А., Поляков С. Л. Внутриполостное ультразвуковое исследование в диагностике рака мочевого пузыря и предстательной железы. Новости луч. диагн. 2001; 1-2: 40-46.
  18. Chodak G. W., Keller P., Schoenberg H. W. Assessment of screening for prostate cancer using the digital rectal examination. J. Urol. (Baltimore) 1989; 141 (5): 1136-1138.
  19. Donohue R. E., Fauver H. E., Whitesel J. A. Staging prostatic cancer: a different distribution. Ibid. 1979; 122 (3): 327-329.
  20. Wajsman Z., Chy Т. М. Detection and diagnosis of prostatic cancer. In: Murphy G. P., ed. Prostatic cancer. Massachusetts: Littleton; 1987. 94-99.
  21. Thompson I. M., Ziedman E. J. Presentation and clinical course of patients ultimately succumbing to carcinoma of prostate. Scand. J. Urol. Nephrol. 1991; 25 (2): 111-114.
  22. Schroder F. H., Cruijsen-Koeter L., deKoning H. J. etal. Prostate cancer detection at low prostate specific antigen. J. Urol. (Baltimore) 2000; 163 (3): 806-812.
  23. Cooner W. H., Mosley B. R., Ruterford C. L. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. Ibid. 1990; 143 (6): 1146-1152.
  24. Smith J. A., Scardino P. Т., Resnick M. I. et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. Ibid. 1997; 157 (3): 902-906.
  25. Carter H. P., Hamper U. M., Sheth S. et al. Evaluation of transrectal ultrasound in the early detection of prostate cancer. Ibid. 1989; 142 (4): 1008-1010.
  26. Waterhouse R. L., Resnick M. I. The use of transrectal prostatic ultrasonography in the evaluation of patients with prostatic carcinoma. Ibid. 141 (2): 233-239.
  27. Cooner W. H., Mosley B. R., Rutherfoid С. L. et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. Ibid. 1988; 139 (4): 758-761.
  28. Scardino P. T. Early detection of prostate cancer. Adv. Urol. Ultrasound 1989; 16 (4): 635-655.
  29. Catalona W. J., Smith D. S., Ratliff T. L. et al. Detection of organconfined prostate cancer is increased through prostate specific antigen-based screening. J. A. M. A. 1993; 270 (3): 948-954.
  30. Babaian R. J., Mettlin C., Kane R. et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992; 69 (2): 1193-1200.
  31. Лоран О. Б., Пушкарь Д. Ю., Степанов В. Н., Крохотина Л. В. Дифференциальная диагностика опухолей предстательной железы с помощью определения уровня простатспецифического антигена сыворотки крови. М.; 2000.
  32. Mettlin С., Murphy G. P., Lee F. et al. Characteristics of prostate cancers detected in a multimodality early detecting program. Cancer 1993; 72 (5): 1701-1708.
  33. Morote J., Encabo G., de Torres I. M. Use of present free prostatespecific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur. Urol. 2000; 38: 225-229.
  34. Лоран О. Б., Пушкарь Д. Ю., Франк Г. А. Простат-специфический антиген и морфологическая характеристика рака предстательной железы: Руководство для врачей. М.: Медпресс; 1999.
  35. Catalona W. J., Richie J. P., Ahmann F. K. et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6.630 men. J. Urol. (Baltimore) 1994; 151: 1283-1286.
  36. Epstein J. I., Walsh P. C., Camichael M. et al. Pathologic and clinical findings to predict tumor extent on nonpalpable (stage Tic) prostate cancer. J. A. M. A. 1994; 271 (3): 368-374.
  37. Kleer E., Larsen-Keller J. J., Zincke H. Ability of preoperative serum prostate specific Antigen value to predict pathological stage and DNA ploidy: influence of clinical stage and tumor grade. Urology 1993; 40: 207.
  38. Smith D. S., Carvalhal G. F., Mager D. E. et al. Use of lower prostate-specific antigen cutoffs for prostate cancer screening in black and white men. J. Urol. (Baltimore) 1998; 160 (5): 1734-1738.
  39. Lodding P., Aus G., Bergdahl S. et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. prostate specific antigen. Ibid. 159 (3): 899-903.
  40. Smith D. S., Catalona W. J., Herschman J. D. Longitudinal screening for prostate cancer with prostate-specific antigen. J. A. M. A. 1996; 276 (16): 1309-1315.
  41. Harris С. H., Dalkin B. J., Martin E. et al. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4 ng/ml. or less. J. Urol. (Baltimore) 1997; 157 (5): 1740-1743.
  42. Demura Т., Watarai Y., Togashi M. et al. Measurement of prostate specific antigen and gammaseminoprotein ratio: a new means to distinguish benign prostatic hyperplasia and prostate cancer. Ibid. 1993; 150 (5, pt 2): 1740-1745.
  43. Lilja H. Significance of different molecular forms of serum PSA: form of PSA versus that complexed to the free, noncomplexed to alpha 1-antichymottrypsine. Urol. Clin. N. Am. 1993; 20 (4): 681-686.
  44. Recker F., Kwiatkowski M. K., Piironen T. et al. Free-to-total prostate specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patient with prostatism and intermediate PSA levels. Br. J. Urol. 1998; 81 (4): 532-538.
  45. Jung K., Meyer А., Lien M. et al. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patient with prostate cancer from those with chronic inflammation of the prostate. J. Urol. (Baltimore) 1998; 159 (5): 1595-1598.
  46. Catalona W. J., Smith D. S., Wolfert R. L. et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity prostate cancer screening. J. A. M. A. 1995; 274 (5): 1214-1220.
  47. Bangma C. N., Kranse R., Blijenberg B. G. et al. The value of screening test in the detection of prostate cancer: part I - results of a retrospective evaluation of 1726 men. Urology 1995; 46 (6): 773-778.
  48. Vashi A. R., Wojno К. J., Henricks W. et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Ibid. 1997; 49 (1):P 19-27.
  49. Catalona W. J., Partin A. W., Slawin К. M. et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. A. M. A. 1998; 279 (19): 1542-1547.
  50. Morote J., Encabo G., Lopez M. A. et al. The free-to-total serum prostate specific antigen ratio as a predictor of the pathological features of prostate cancer. Br. J. Urol. 1999; 83: 1003-1006.
  51. Chen Y. Т., Luderer A. A., Thiel R. P. et al. Using proportions of free to total prostate specific antigen, age, and total prostate specific antigen to predict the probability of prostate cancer. Urology 1996; 47 (4): 518-524.
  52. Van Cangh P. J., De Nayer P., De Vischer L. et al. Free-to-total prostate specific antigen ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1,8 to 10 ng/ml total PSA. Ibid. 1996; 48 (6A, suppl.): 67-70.
  53. Partin A. W., Catalona W. J., Southwick P. C. et al. Analysis of percent free prostate specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Ibid. 55-61.
  54. Arcangeli C. G., Humphrey P. A., Smith D. S. et al. Percentage of free serum PSA as a predictor of the pathological feAtures of prostate cancer in a screening population. Ibid. 1998; 51: 558.
  55. Southwick P. C., Catalona W. J., Partin A. W. et al. Prediction of postradical prostatectomy outcome for stage Tic prostate cancer with % free PSA: A prospective multicenter clinical trial. J. Urol. (Baltimore) 1999; 162: 1346-1351.
  56. Carter H. В., Pearson J. D., Metter E. J. et al. Longitudinal evaluation of prostate specific antigen levels in men and without prostate disease. J. A. M. A. 1992; 267 (16): 2215-2220.
  57. Carter H. В., Chan D. W., Pearson J. D. et al. Prostate specific antigen variability in men without prostate cancer: effect of sampling interval on prostate specific antigen velocity. Urology 1995; 45 (4): 591-596.
  58. Prestigiacomo A. F., Stamey T. A. Physiological variation of serum prostate specific antigen in the 4,0 to 10,0 ng/ml. range in male volunteers. J. Urol. (Baltimore) 1996; 155 (6): 1977-1980.
  59. Brawer M. K., Beate J., Wener M. H. et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. Ibid. 1993; 150 (1): 106-109.
  60. Bangma C. N., Kranse R., Blijenberg B. G., Schroder F. H. The free-to-total serum prostate specific antigen ratio for staging prostatic carcinoma. Ibid. 1997; 157 (2): 544-547.
  61. Benson N. C., Wang I. S., Ponluck K. A. et al. Prostate specific antigen density: a means of distinguishing benign prostatic hyperplasia and prostate cancer. Ibid. 1992; 147: 815-819.
  62. Diamandis E. P., Yu H. Editorial: new biological functions of prostate specific antigen? J. Clin. Endocrinol. Metab. 1995; 80 (5): 1515-1517.
  63. Partin A. W., Oesterling J. E. The clinical usefulness of prostate specific antigen: update 1994. J. Urol. (Baltimore) 1994; 152 (5, pt 1): 1358-1368.
  64. Gleason D. F. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M., ed. Urologic pathology: The prostate. Philadelphia: Lea and Febiger; 1977.
  65. Thickman D., Speers W. C., Philpott P. J. et al. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer. J. Urol. (Baltimore) 1996; 156: 110-113.
  66. Cookson M. S., Fleshner N. E., Soloway S. M. et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: Accuracy and clinical application. Ibid. 1997; 157: 559-562.
  67. Rubin M. A., Mucci N. R., Manley S. et al. Predictors of Gleason pattern 4/5 prostate cancer and prostatectomy specimens: can high grade tumor be predicted preoperatively. Ibid. 2001; 165: 114-118.
  68. Epstein J. I. Critical issues in grading of adenocarcinomas of the prostate. Can. J. Urol. 1997; suppl. 2: 28-33.
  69. Eskew L. A., Bare R. L., McCullough D. L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol. (Baltimore) 1997; 157: 199-203.
  70. Livene M. A., Ittman M., Melamed J. et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate on predicting Gleason score of prostate cancer. Ibid. 1998; 159: 471-476.
  71. Uzzo R. G., Wei J. Т., Waldbaum R. S. et al. The influence of prostate size one cancer detection. Urology 1995; 46: 831-836.
  72. Karakiewicz P. L, Bazinet M., Aprikian A. G. et al. Outcome of sextant biopsy according to gland volume. Ibid. 1997; 49: 55-58.
  73. Bangma С. H., Huland H., Schroder F. H., van Cangh P. J. ESU Course "Early diagnosis and treatment of localized prostate cancer". Geneva; 2001; 22: 1-10.
  74. Crawford E. D., Hirano D., Werahera P. N. et al. Computer modeling of prostate biopsy: tumor size and location - not clinical significance - determine cancer detection. J. Urol. (Baltimore) 1998; 159 (4): 1260-1264.
  75. Keetch D. W., McMurtry J. M., Smith D. S. et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in man with initially negative prostate biopsies. Ibid. 1996; 156 (2, ptl): 428-431.
  76. Chang J. J., Shinohara K., Bhargava V. et al. Prospective evaluation lateral biopsies of the peripheral zone for prostate cancer detection. Ibid. 1998; 160: 2111-2115.
  77. Norberg M., Egevad L., Holmberg L. et al. The sextant protocol for ultrasound guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 562-565.
  78. Schmid H. P., McNeal J. E. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am. J. Surg. Pathol. 1992; 16 (2): 184-191.
  79. Berges R. R., Vukanovich J., Epstein T. J. et al. Implication of cell kinetic changes during the progression of human prostate cancer. Clin. Cancer Res. 1995; 1: 473-477.
  80. Schmid H. P., McNeal J. E., Stamey T. A. Observations on the doubling time of prostate cancer. The use of serial prostate specific antigen in patients with untreated diseases as a measure of increasing cancer volume. Cancer 1993; 71: 2031-2040.
  81. Cupp M. R., Bostwick D. G., Myers R. P. et al. The volume of prostate cancer in the biopsy specimens cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J. Urol. (Baltimore) 1995; 153: 1543-1548.
  82. Stamey T. A., Freiha F. S., McNeal J. E. et al. Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-938.
  83. Ravery V., Schmid H. P., Toublanc M. et al. Is the percentage of cancer in biopsy cores predictive of extracapsular diseases in T1-T2 prostate carcinoma? Ibid. 1996; 78: 1079-1084.
  84. Sebo T. J., Bock B. J., Cheville J. C. et al. The presence of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J. Urol. (Baltimore) 2000; 163: 174-178.
  85. Taneja S. S., Penson D. V., Epelbaum A. et al. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in prostatectomy surgical specimen? Ibid. 1999; 162: 1352-1358.
  86. Rogatsch H., Horniger W., Volgger H. et al. Radical prostatectomy: The value of preoperative, individually labeled apical biopsies. Ibid. 2000; 164: 754-758.
  87. Egan A. J., Bostwick D. G. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks independent significance. Lab. Invest. 1997; 76: 421.
  88. Poste A. W., Fidler I. J. The pathogenesis of cancer. Nature 1980; 283: 139-146.
  89. Clemente С. G., Boracchi P., Andreola S. et al. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992; 69: 1396-1403.
  90. Chodak G. W., Haudenschild G., Gittes R. F. et al. Angiogenetic activity as a marker of neoplastic and perineoplastic lesions of the human bladder. Ann. Surg. 1980; 192: 762-771.
  91. Sillman F., Boyce J., Fruchter R. The significance of atypical vessels and neovascularization in cervical neoplasia. Am. J. Obstet. Gynecol. 1981; 139: 154-159.
  92. Blood С. H., Zetter B. R. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Arch. Pathol. Lab. Med. 1995; 119: 1045-1049.
  93. Bahnson R. R., Dresner S. M., Gooding W. et al. Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate 1989; 15: 149-155.
  94. Salomao D. R., Graham S. D., Bostwick D. G. Microvascular invasion in prostate cancer correlated with pathologic stage. Arch. Pathol. Lab. Med. 1995; 119: 1050-1054.
  95. McNeal J. E., Yemoto С. Е. Significance of demonstrable vascular space invasion for the progression of prostate adenocarcinoma. Am. J. Surg. Pathol. 1996; 20: 1351-1360.
  96. van den Ouden D., Kranse R., Hop W. G. et al. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol. Int. 1998; 60: 17-24.
  97. Taille A., Rubin M. A., Buttyan R. et al. Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate cancer patients? Eur. Urol. 2000; 38: 79-84.
  98. Yorukoglu K., Sagol O., Ozkara E. et al. Comparison of microvascularization in diagnostic needle biopsy and radical prostatectomy in prostatic carcinoma. Ibid. 1999; 35: 109-112.
  99. Rogatsch H., Hittmair A., Reissigl A. et al. Microvessel density in core biopsies of prostatic adenocarcinoma: A Stage Predictor? J. Pathol. 1997; 182: 205-210.
  100. Bostwick D. G., Wheeler T. M., Blute M. et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48: 47-57.
  101. Brincer D. A., Ross J. S., Tran Т. Н. et al. Can ploidy of prostate carcinoma diagnosed on needle biopsy to predict radical prostatectomy stage and grade? J. Urol. (Baltimore) 1999; 162: 2036-2039.
  102. Partin A. W., Yoo J., Carter H. B. et al. The use of prostatic specific antigen, clinical stage end gleason score to predict pathological stage in men with localized prostatic cancer. Ibid. 1993; 150: 110-114.
  103. Partin A. W., Mangold L. A., Lamm D. M. et al. Contemporary update of prostate cancer staging nomograms (partin tables) for the new millennium. Urology 2001; 58: 843-848.
  104. Stamey T. A., McNeal J. E., Yemoto С. М. et al. Biological determinants of cancer progression in men with prostate cancer. J. A. M. A. 1999; 281: 1395-1400.
  105. HulandH. Radical prostatectomy: options and issues. Eur. Urol. 2001; 39 (suppl. 1): 3-9.
  106. Conrad S., Graefen M., Pichlmier U. et al. Systematic prostate biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J. Urol. (Baltimore) 1998; 159: 2023-2029.
  107. Myers R. P., Cahill D. R., Devine R. M. et al. Anatomy of radical prostatectomy as defined by magnetic resonance imaging. Ibid. 2148-2158.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies